U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
[x] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
--------------------------------------------------------------------------------
1. Name and Address of Reporting Person*
H. Lundbeck A/S
--------------------------------------------------------------------------------
(Last) (First) (Middle)
9 Ottiliavej DK-2500 Valby
--------------------------------------------------------------------------------
(Street)
Copenhagen, Denmark
--------------------------------------------------------------------------------
(City) (State) (Zip)
--------------------------------------------------------------------------------
2. Issuer Name and Ticker or Trading Symbol
Synaptic Pharmaceutical Corporation (SNAP)
--------------------------------------------------------------------------------
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
--------------------------------------------------------------------------------
4. Statement for Month/Year
March 6, 2003
--------------------------------------------------------------------------------
5. If Amendment, Date of Original (Month/Year)
--------------------------------------------------------------------------------
6. Relationship of Reporting Person to Issuer
(Check all applicable)
[_] Director [x] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
--------------------------------------------------------------------------------
7. Individual or Joint/Group Filing (Check applicable line)
[x] Form filed by one Reporting Person
[_] Form filed by more than one Reporting Person
--------------------------------------------------------------------------------
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
5.
Amount of 6.
4. Securities Owner-
Securities Acquired (A) or Beneficially ship
2A. 3. Disposed of (D) Owned Form: 7.
Deemed Transaction (Instr. 3, 4 and 5) Following Direct Nature of
2. Execution Code --------------------------- Reported (D) or Indirect
1. Transaction Date, (Instr. 8) (A) Transaction(s) Indirect Beneficial
Title of Security Date if any ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (mm/dd/yy) (mm/dd/yy) Code V (D) and 4) (Instr.4) (Instr. 4)
-----------------------------------------------------------------------------------------------------------------------------------
Common Stock, par value 3/06/03 J(1) 12,085,055 A $6.50 per 12,085,055 D
$0.01 per share share
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
================================================================================
FORM 4 (continued)
TABLE II -- DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED
(E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)
================================================================================
9. 10.
Number of Owner-
Deriv- ship
ative Form
2. Secur- of
Conver- 5. 7. ities Deriv- 11.
sion Number of Title and Amount Bene- ative Nature
or Derivative 6. of Underlying 8. ficially Secur- of
Exer- 4. Securities Date Securities Price Owned ity: In-
cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of Follow- Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- ing (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative Reported In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- Transac- direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity tions (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
------------------------------------------------------------------------------------------------------------------------------------
Series B
Convertible
Preferred Stock, par
value $0.01 per Common
share $4.3358 3/06/03 J(2) 9,438 Stock 2,176,760 9,438 D
------------------------------------------------------------------------------------------------------------------------------------
Series C
Convertible
Preferred
Stock, par
value $0.01 Common
per share $5.9713 3/06/03 J(3) 25,562 Stock 4,280,809 25,562 D
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
================================================================================
Explanation of Responses:
(1) Pursuant to the terms of the Agreement and Plan of Merger (the "Merger
Agreement") dated as of November 21, 2002, among H. Lundbeck A/S ("Lundbeck"),
Viking Sub Corporation ("Viking Sub") and Synaptic Pharmaceutical Corporation
("Synaptic"), the merger (the "Merger") of Viking Sub with and into Synaptic
became effective on March 6, 2003. At the effective time of the Merger,
Synaptic had 12,085,055 shares of common stock, par value $0.01 per share (the
"Common Stock"), outstanding. Under the terms of the Merger Agreement, at the
effective time of the Merger, each outstanding share of Common Stock was
converted into the right to receive $6.50 in cash, without interest. At the
effective time of the Merger, Lundbeck became the beneficial owner of all
12,085,055 shares of Common Stock. Synaptic is now a wholly owned subsidiary
of Lundbeck. In addition, pursuant to the terms of the Merger Agreement, the
Common Stock ceased to be quoted on The Nasdaq Stock Market at the close of
business on March 6, 2003, and it will no longer be publicly traded.
(2) At the effective time of the Merger, Synaptic had 9,438 shares of Series B
Convertible Preferred Stock, par value $0.01 per share (the "Series B
Preferred Stock"), outstanding. Pursuant to the terms of the Merger Agreement,
at the effective time of the Merger, each outstanding share of Series B
Preferred Stock was converted into the right to receive $1,499.15 in cash,
without interest, and ceased to be outstanding.
(3) At the effective time of the Merger, Synaptic had 25,562 shares of Series
C Convertible Preferred Stock, par value $0.01 per share (the "Series C
Preferred Stock"), outstanding. Pursuant to the terms of the Merger Agreement,
at the effective time of the Merger, each outstanding share of Series C
Preferred Stock was converted into the right to receive $1,088.54 in cash,
without interest, and ceased to be outstanding.
/s/ Claus Braestrup March 6, 2003
--------------------------------------------- -----------------------
**Signature of Reporting Person Date
** Intentional misstatements or omissions of facts constitute Federal
Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Page 2 of 2